AR021751A1 - MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS - Google Patents

MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS

Info

Publication number
AR021751A1
AR021751A1 ARP990103922A ARP990103922A AR021751A1 AR 021751 A1 AR021751 A1 AR 021751A1 AR P990103922 A ARP990103922 A AR P990103922A AR P990103922 A ARP990103922 A AR P990103922A AR 021751 A1 AR021751 A1 AR 021751A1
Authority
AR
Argentina
Prior art keywords
alkyl
different
alkyloxy
group
substituted
Prior art date
Application number
ARP990103922A
Other languages
Spanish (es)
Original Assignee
Menarini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Ricerche Spa filed Critical Menarini Ricerche Spa
Publication of AR021751A1 publication Critical patent/AR021751A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/22Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos monocíclicos de la formula general (1) donde: X1, X2, X3, X4, ya sean iguales o diferentes, forman un grupo seleccionado entre: -CONR-, -NRCO-,-CH2-NR-, -NR-CH2- donde R es H, alquilo C1-3, bencilo; f y m, ya sean iguales o diferentes, sonun numero seleccionado entre 0, 1 y 2; R1 y R2, ya seaniguales o diferentes, forman un grupo -(CH2)r-Ar, donde r es igual a 0, 1, 2 y Ar es un grupo aromático seleccionado entre: benceno, naftalina, tiofeno,benzotiofeno, piridina, quinolina, indol,furano, benzofuran, tiazol, benzotiazol, imidazol, benzoimidazol, con posibilidad de sustitucion por medio de hasta 2sustitutos seleccionados entre alquilo C1-3, haloalquilo, alquiloxi C1-3, amino C2-4-alquiloxi, halogenos, OH, NH2, CN, NR6R7, dondeR6 y R7, ya sean iguales odiferentes, son H o alquilo C1-3; R3 es un grupo seleccionado entre los siguientes grupos: -(CH2)r-Ar1 donde r es igual a 0, 1, 2 y Ar1 es un grupo aromáticoseleccionado entre: benceno, naftalina, tiofeno, benzotiofeno, piridina, quinolina, indol, furano, benzofurano, tiazol, benzotiazol, imidazol, benzoimidazol,con posibilidad de sustitucion por medio de hasta 2 sustitutos seleccionados entre alquilo C1-3 y haloalquilo, alquiloxi C1-3 y amino alquiloxi, halogenos, OH,NH2, CN, NR6R7, donde R6 y R7, ya sean iguales o diferentes, son H o alquilo C1-3; R5 es H; R4 es un grupo seleccionado entre: -NR8R9, donde R8 es H o alquiloC1-3 y R9 es un metanosulfonilo, tosilo, tetrahidropiranilo, tetrahidrotiopiranilo, posiblemente mono o bisustituido por oxígeno en el átomo S, piperidiloposiblemente sustituido en el átomo N por un alquilo C1-3, acilo C1-3, amino sulfonilo, metanosulfonilo; o un grupo (CH2)g-R10 donde g es 1, 2, 3 y R10 seselecciona entre morfolino, furano,CN; o R8 y R9 junto con el átomo N al que están vinculados forman piperacina posiblemente sustituida en uno de susnitrogenos por alquilo C1-3, acilo C1-3 o metanosulfonilo; N(R11)CO(CH2)h-R12 donde R11 es H o alquilo C1-3; h es 0, 1, 2, 3; y R12 seselecciona entre:morfolino, pirrolidino posiblemente sustituido por hidroxi o hidroximetil, piperidina posiblemente sustituido por un grupo hidroxicarboxilamido oMonocyclic compounds of the general formula (1) where: X1, X2, X3, X4, whether the same or different, form a group selected from: -CONR-, -NRCO -, - CH2-NR-, -NR-CH2- where R is H, C1-3 alkyl, benzyl; f and m, whether the same or different, are a number selected from 0, 1 and 2; R1 and R2, whether equal or different, form a group - (CH2) r-Ar, where r is equal to 0, 1, 2 and Ar is an aromatic group selected from: benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline , indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, with the possibility of substitution by means of up to 2 substitutes selected from C1-3 alkyl, haloalkyl, C1-3 alkyloxy, C2-4-alkyloxy, halogens, OH, NH2 , CN, NR6R7, where R6 and R7, whether equal or different, are H or C1-3 alkyl; R3 is a group selected from the following groups: - (CH2) r-Ar1 where r is equal to 0, 1, 2 and Ar1 is an aromatic group selected from: benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan , benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, with the possibility of substitution by means of up to 2 substitutes selected from C1-3 alkyl and haloalkyl, C1-3 alkyloxy and amino alkyloxy, halogens, OH, NH2, CN, NR6R7, where R6 and R7, whether the same or different, are H or C1-3 alkyl; R5 is H; R4 is a group selected from: -NR8R9, where R8 is H or C1-3alkyl and R9 is a methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl, possibly mono or bis-substituted by oxygen in the S atom, piperidylpossibly substituted on the N atom by an alkyl C1-3, C1-3 acyl, amino sulfonyl, methanesulfonyl; or a group (CH2) g-R10 where g is 1, 2, 3 and R10 is selected from morpholino, furan, CN; or R8 and R9 together with the N atom to which they are linked form piperazine possibly substituted in one of susnitrogens by C1-3 alkyl, C1-3 acyl or methanesulfonyl; N (R11) CO (CH2) h-R12 where R11 is H or C1-3 alkyl; h is 0, 1, 2, 3; and R12 is selected from: morpholino, pyrrolidino possibly substituted by hydroxy or hydroxymethyl, piperidine possibly substituted by a hydroxycarboxylamide group or

ARP990103922A 1998-08-05 1999-08-05 MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS AR021751A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998FI000186A IT1304888B1 (en) 1998-08-05 1998-08-05 MONOCYCLIC ACTION COMPOUNDS NK-2 ANTAGONIST AND FORMULATIONS THAT CONTAIN

Publications (1)

Publication Number Publication Date
AR021751A1 true AR021751A1 (en) 2002-08-07

Family

ID=11352646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103922A AR021751A1 (en) 1998-08-05 1999-08-05 MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS

Country Status (11)

Country Link
EP (1) EP1102789A1 (en)
JP (1) JP2002522450A (en)
AR (1) AR021751A1 (en)
AU (1) AU5507999A (en)
CA (1) CA2339638A1 (en)
CO (1) CO5080789A1 (en)
IT (1) IT1304888B1 (en)
PE (1) PE20001002A1 (en)
TR (1) TR200100354T2 (en)
TW (1) TW491857B (en)
WO (1) WO2000008046A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307809B1 (en) * 1999-10-21 2001-11-19 Menarini Ricerche Spa BASIC MONOCYCLIC COMPOUNDS WITH NK-2 ANTAGONIST ACTION, MANUFACTURING PROCESSES AND FORMULATIONS CONTAINING THEM.
PL217630B1 (en) 2003-04-24 2014-08-29 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
UY38485A (en) 2018-11-27 2020-06-30 Novartis Ag CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
AU2387592A (en) * 1991-08-08 1993-03-02 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Cyclic hexapeptides as tachyquinin antagonists, their preparation and pharmaceutical compositions thereof
ATE155486T1 (en) * 1991-08-13 1997-08-15 Takeda Chemical Industries Ltd CYCLIC PEPTIDES AND THEIR USE
IT1277835B1 (en) * 1995-03-13 1997-11-12 Menarini Farma Ind BICYCLE COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS
IT1291776B1 (en) * 1997-02-07 1999-01-21 Menarini Ricerche Spa MONOCYCLIC COMPOUNDS WITH FOUR BIFUNCTIONAL RESIDUES, HAVING NK-2 ANTAGONIST ACTION

Also Published As

Publication number Publication date
JP2002522450A (en) 2002-07-23
WO2000008046A1 (en) 2000-02-17
CO5080789A1 (en) 2001-09-25
AU5507999A (en) 2000-02-28
IT1304888B1 (en) 2001-04-05
CA2339638A1 (en) 2000-02-17
EP1102789A1 (en) 2001-05-30
PE20001002A1 (en) 2000-10-16
TW491857B (en) 2002-06-21
TR200100354T2 (en) 2001-05-21
ITFI980186A1 (en) 2000-02-05

Similar Documents

Publication Publication Date Title
RU2203272C2 (en) Substituted bicyclic compounds, parent and intermediate substances for their synthesis and pharmaceutical composition based on thereof
UY27322A1 (en) NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER
AR055878A1 (en) CYCLOPROPANOCARBOXAMIDE DERIVATIVES
ES2185665T3 (en) DERIVATIVES OF BENZOFURAN AS AN TAGYCIN ANTAGONISTS.
ES2082013T3 (en) MUSCARINIC RECEPTOR ANTAGONISTS.
ES2150918T3 (en) 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINAS 1-SUBSTITUTED; INTERMEDIATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS.
PE20030431A1 (en) QUINUCLIDINE DERIVATIVES AS AGONISTS OF THE NICOTINE RECEPTOR OF ACETYLCHOLINE TYPE a7
EA200970704A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTAGONISTS OF NK1 RECEPTOR AND NA CHANNEL BLOCKERS
UY27336A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
ES2157593T3 (en) DERIVED FROM THE HETEROCICLIC ADENOSINE REPLACED IN N6.
ES2064310T3 (en) PROCEDURE FOR PREPARING IMIDAZOPYRIDINE COMPOUNDS.
PE20030257A1 (en) 8-AZA-11-DEOXY-PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS
IS2503B (en) New compounds
PE20060457A1 (en) DIPHENYL ETHER DERIVATIVES AS ANTAGONISTS OF 5HT2 RECEPTORS
MX2009007914A (en) Novel pharmaceutical compositions.
YU53100A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
ES2059873T3 (en) 2-ALKYNYLPHENOLS SUBSTITUTED WITH ANTI-INFLAMMATORY ACTIVITY, A PROCEDURE FOR ITS PREPARATION AND ITS PHARMACEUTICAL COMPOSITIONS.
UY24429A1 (en) ACETIDINS
AR021751A1 (en) MONOCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS AN ANTAGONIST OF NK2 TAQUIQUININE RECEIVER IN THE TREATMENT OF DEPATOLOGIES WHERE THERE IS RELEASE OF TACHIQUININS
ES2045126T3 (en) THERAPEUTIC AGENTS.
AR006189A1 (en) AMINOALKYL-ETERS AND ACILAMINOALKYL-ETERES, PROCEDURE FOR THEIR PREPARATION AND USE AS BRADIQUININE RECEPTOR ANTAGONISTS
AR016198A1 (en) A COMPOUND THAT IS A DISTAMICIN DERIVATIVE REPLACED WITH ACRYLILE, ITS USE, A PROCEDURE TO PREPARE IT AND A PHARMACEUTICAL COMPOSITION THAT LOCOMPRESSES
PE20030611A1 (en) LINEAR BASIC COMPOUNDS THAT HAVE ANTAGONIST ACTIVITY OF NK-2 AND ITS FORMULATIONS
AR065208A1 (en) DERIVATIVES OF TETRAHYDRONAFTALENE SUBSTITUTED WITH HETEROCICLES OR ITS BENEFITED ANALOGS, METHOD OF PREPARATION, MEDICINES CONTAINING THEMSELVES AND USES OF THE SAME, AS LEGENDS OF RECEPTORS 5-HT7, IN PATHOLOGIES ASSOCIATED WITH SNC.
ES2187783T3 (en) INDOLINE DERIVATIVES USEFUL AS ANTAGONISTS OF THE 5-HT-2C RECEIVER.